John A. Violet

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Acute exercise induces distinct quantitative and phenotypical T cell profiles in men with prostate cancer.

Acute exercise induces distinct quantitative and phenotypical T cell profiles in men with prostate cancer.

Journal: Frontiers in sports and active living

Published: February 24, 2023

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.

Journal: Lancet (London, England)

Published: December 22, 2020

Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy.

Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy.

Journal: European urology focus

Published: September 10, 2020

Natural killer cell mobilization and egress following acute exercise in men with prostate cancer.

Natural killer cell mobilization and egress following acute exercise in men with prostate cancer.

Journal: Experimental physiology

Published: March 18, 2020

Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617.

Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617.

Journal: European journal of nuclear medicine and molecular imaging

Published: December 11, 2019

TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).

TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).

Journal: BJU international

Published: October 23, 2019

Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer.

Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: September 09, 2019

Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors.

Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: September 03, 2019

Going nuclear: it is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team.

Going nuclear: it is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team.

Journal: BJU international

Published: May 26, 2019

Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies.

Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies.

Journal: Prostate cancer and prostatic diseases

Published: April 21, 2019

Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics.

Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics.

Journal: European urology

Published: December 12, 2018

Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy.

Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy.

Journal: European urology oncology

Published: September 15, 2018

Showing 1-12 of 25

Last Updated: 09/26/2026